Skip to main content
SpringerLink
Log in

Mitochondrial Enhancement for Neurodegenerative Movement Disorders: A Systematic Review of Trials Involving Creatine, Coenzyme Q10, Idebenone and Mitoquinone

  • Systematic Review
  • Published:
CNS Drugs Aims and scope Submit manuscript

Abstract

Background

Neurodegenerative movement disorders mainly include Parkinson’s disease (PD), atypical parkinsonisms, Huntington’s disease (HD), and Friedreich’s ataxia (FA). With mitochondrial dysfunction observed in these diseases, mitochondrial enhancement such as creatine, coenzyme Q10 (CoQ10) and its analogues (idebenone and mitoquinone) has been regarded as a potential treatment.

Aim

In this paper, we systematically analysed and summarized the efficacy of mitochondrial enhancement in improving motor and other symptoms in neurodegenerative movement disorders.

Methods

We searched the electronic databases PubMed, EMBASE, CINAHL, Cochrane Library and China National Knowledge Infrastructure until September 2013 for eligible randomized controlled trials (RCTs), as well as unpublished and ongoing trials. We calculated the mean differences for continuous data with 95 % confidence intervals and pooled the results using a fixed-effect model, if no significant statistical heterogeneity was found (I 2 < 50 %).

Results

We included 16 studies with 1,557 randomized patients, which compared creatine, CoQ10 or its analogues with placebo in motor and other symptoms. No significant improvements were found in the motor symptoms of PD, atypical parkinsonisms or HD patients, while only the high dose of idebenone seems to be promising for motor improvement in FA. Certain benefits are found in other symptoms.

Conclusions

There is insufficient evidence to support the use of mitochondrial enhancement in patients with neurodegenerative movement disorders. More well-designed RCTs with large samples are required for further confirmation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Chaturvedi RK, Beal MF. Mitochondrial approaches for neuroprotection. Ann N Y Acad Sci. 2008;1147:395–412.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  2. Horvath TL, Diano S, Leranth C, Garcia-Segura LM, Cowley MA, Shanabrough M, et al. Coenzyme Q induces nigral mitochondrial uncoupling and prevents dopamine cell loss in a primate model of Parkinson’s disease. Endocrinology. 2003;144:2757–60.

    Article  CAS  PubMed  Google Scholar 

  3. Matthews RT, Ferrante RJ, Klivenyi P, Yang L, Klein AM, Mueller G, et al. Creatine and cyclocreatine attenuate MPTP neurotoxicity. Exp Neurol. 1999;157:142–9.

    Article  CAS  PubMed  Google Scholar 

  4. Harada S, Fujii C, Hayashi A, Ohkoshi N. An association between idiopathic Parkinson’s disease and polymorphisms of phase II detoxification enzymes: glutathione S-transferase M1 and quinone oxidoreductase 1 and 2. Biochem Biophys Res Commun. 2001;288:887–92.

    Article  CAS  PubMed  Google Scholar 

  5. Giorgio V, Petronilli V, Ghelli A, Carelli V, Rugolo M, Lenaz G, et al. The effects of idebenone on mitochondrial bioenergetics. Biochim Biophys Acta. 2012;1817:363–9.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  6. The Multiple-System Atrophy Research Collaboration. Mutations in COQ2 in familial and sporadic multiple-system atrophy. N Engl J Med. 2013;369:233–44.

    Article  Google Scholar 

  7. Tsou AY, Friedman LS, Wilson RB, Lynch DR. Pharmacotherapy for Friedreich ataxia. CNS Drugs. 2009;23:213–23.

    Article  CAS  PubMed  Google Scholar 

  8. Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from http://www.cochrane-handbook.org.

  9. Bender A, Koch W, Elstner M, Schombacher Y, Bender J, Moeschl M, et al. Creatine supplementation in Parkinson disease: a placebo-controlled randomized pilot trial. Neurology. 2006;67:1262–4.

    Article  CAS  PubMed  Google Scholar 

  10. Hass CJ, Collins MA, Juncos JL. Resistance training with creatine monohydrate improves upper-body strength in patients with Parkinson disease: a randomized trial. Neurorehabil Neural Repair. 2007;21:107–15.

    Article  PubMed  Google Scholar 

  11. Müller T, Buttner T, Gholipour AF, Kuhn W. Coenzyme Q10 supplementation provides mild symptomatic benefit in patients with Parkinson’s disease. Neurosci Lett. 2003;341:201–4.

    Article  PubMed  Google Scholar 

  12. The NINDS NET-PD Investigators. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology. 2006;66:664–71.

    Article  Google Scholar 

  13. The NINDS NET-PD Investigators. A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease. Neurology. 2007;68:20–8.

    Article  Google Scholar 

  14. Shults CW, Oakes D, Kieburtz K, Beal MF, Haas R, Plumb S, et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol. 2002;59:1541–50.

    Article  PubMed  Google Scholar 

  15. Snow BJ, Rolfe FL, Lockhart MM, Frampton CM, O’Sullivan JD, Fung V, et al. A double-blind, placebo-controlled study to assess the mitochondria-targeted antioxidant MitoQ as a disease-modifying therapy in Parkinson’s disease. Mov Disord. 2010;25:1670–4.

    Article  PubMed  Google Scholar 

  16. Storch A, Jost WH, Vieregge P, Spiegel J, Greulich W, Durner J, et al. Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease. Arch Neurol. 2007;64:938–44.

    Article  PubMed  Google Scholar 

  17. Stamelou M, Reuss A, Pilatus U, Magerkurth J, Niklowitz P, Eggert KM, et al. Short-term effects of coenzyme Q10 in progressive supranuclear palsy: a randomized, placebo-controlled trial. Mov Disord. 2008;23:942–9.

    Article  PubMed  Google Scholar 

  18. Hersch SM, Gevorkian S, Marder K, Moskowitz C, Feigin A, Cox M, et al. Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2’dG. Neurology. 2006;66:250–2.

    Article  CAS  PubMed  Google Scholar 

  19. The Huntington Study Group. A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington’s disease. Neurology. 2001;57:397–404.

    Google Scholar 

  20. Ranen NG, Peyser CE, Coyle JT, Bylsma FW, Sherr M, Day L, et al. A controlled trial of idebenone in Huntington’s disease. Mov Disord. 1996;11:549–54.

    Article  CAS  PubMed  Google Scholar 

  21. Di Prospero NA, Baker A, Jeffries N, Fischbeck KH. Neurological effects of high-dose idebenone in patients with Friedreich’s ataxia: a randomized, placebo-controlled trial. Lancet Neurol. 2007;6:878–86.

    Article  PubMed  Google Scholar 

  22. Lynch DR, Perlman SL, Meier T. A phase 3, double-blind, placebo-controlled trial of idebenone in friedreich ataxia. Arch Neurol. 2010;67:941–7.

    Article  PubMed  Google Scholar 

  23. Mariotti C, Solari A, Torta D, Marano L, Fiorentini C, Di Donato S. Idebenone treatment in Friedreich patients: one-year-long randomized placebo-controlled trial. Neurology. 2003;60:1676–9.

    Article  CAS  PubMed  Google Scholar 

  24. Schöls L, Zange J, Abele M, Schillings M, Skipka G, Kuntz-Hehner S, et al. L-carnitine and creatine in Friedreich’s ataxia: a randomized, placebo-controlled crossover trial. J Neural Transm. 2005;112:789–96.

    Article  PubMed  Google Scholar 

  25. Lagedrost SJ, Sutton MS, Cohen MS, Satou GM, Kaufman BD, Perlman SL, et al. Idebenone in Friedreich ataxia cardiomyopathy: results from a 6-month phase III study (IONIA). Am Heart J. 2011;161(639–645):e1.

    PubMed  Google Scholar 

  26. Jiménez-Jiménez FJ, Molina JA, de Bustos F, García-Redondo A, Gómez-Escalonilla C, Martínez-Salio A, et al. Serum levels of coenzyme Q10 in patients with Parkinson’s disease. J Neural Transm. 2000;107:177–81.

    Article  PubMed  Google Scholar 

  27. Mischley LK, Allen J, Bradley R. Coenzyme Q10 deficiency in patients with Parkinson’s disease. J Neurol Sci. 2012;318:72–5.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  28. Braissant O. Creatine and guanidinoacetate transport at blood-brain and blood-cerebrospinal fluid barriers. J Inherit Metab Dis. 2012;35:655–64.

    Article  CAS  PubMed  Google Scholar 

  29. James AM, Cochemé HM, Smith RA, Murphy MP. Interactions of mitochondria-targeted and untargeted ubiquinones with the mitochondrial respiratory chain and reactive oxygen species. Implications for the use of exogenous ubiquinones as therapies and experimental tools. J Biol Chem. 2005;280:21295–312.

    Article  CAS  PubMed  Google Scholar 

  30. Esposti MD, Ngo A, Ghelli A, Benelli B, Carelli V, McLennan H, et al. The interaction of Q analogs, particularly hydroxydecyl benzoquinone (idebenone), with the respiratory complexes of heart mitochondria. Arch Biochem Biophys. 1996;330:395–400.

    Article  CAS  PubMed  Google Scholar 

  31. Tai KK, Pham L, Truong DD. Idebenone induces apoptotic cell death in the human dopaminergic neuroblastoma SHSY-5Y cells. Neurotox Res. 2011;20:321–8.

    Article  CAS  PubMed  Google Scholar 

  32. Borowsky B, Warner J, Leavitt BR, Tabrizi SJ, Roos RA, Durr A, et al. 8OHdG is not a biomarker for Huntington disease state or progression. Neurology. 2013;80:1934–41.

    Article  CAS  PubMed  Google Scholar 

  33. Meissner W, Hill MP, Tison F, Gross CE, Bezard E. Neuroprotective strategies for Parkinson’s disease: conceptual limits of animal models and clinical trials. Trends Pharmacol Sci. 2004;25:249–53.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The authors received no financial support for the research, authorship, and/or publication of this article.

Conflict of interest

Jia Liu and Lu-ning Wang declare no conflicts of interest.

Author information

Authors and Affiliations

  1. Department of Geriatric Neurology, Chinese PLA General Hospital, Fuxing Road 28, Beijing, 100853, China

    Jia Liu & Lu-ning Wang

Authors
  1. Jia Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lu-ning Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lu-ning Wang.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Liu, J., Wang, Ln. Mitochondrial Enhancement for Neurodegenerative Movement Disorders: A Systematic Review of Trials Involving Creatine, Coenzyme Q10, Idebenone and Mitoquinone. CNS Drugs 28, 63–68 (2014). https://doi.org/10.1007/s40263-013-0124-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40263-013-0124-4

Keywords

Search

Navigation